Picture of Anthem Biosciences logo

ANTHEM — Anthem Biosciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

India's Anthem Biosciences rises after Citi starts with 'buy' rating

** Citi Research initiates coverage on Anthem Biosciences ANTH.NS with "buy," target price of 870 rupees - representing a 20% premium on last close

** Shares of ANTH rise as much as 3.7% to 750.80 rupees, its highest since October 20, 2025

** Brokerage sees strong growth prospects in the contract research, development and manufacturing segment and increasing revenues from commercial molecules

** ANTH poised for 15–16% revenue growth in FY26E, having recently shown better than peers; expect 19% revenue CAGR over FY27–28E, Citi says

** Anthem's earnings growth and margin expansion are likely to remain resilient due to backward integration and scale-up in commercial manufacturing - Citi

** ANTH rated "strong buy" on avg by 6 analysts covering it; median PT at 772.50 rupees- data compiled by LSEG

** YTD, ANTH up 13.5%

 (Reporting by Brijesh Patel in Bengaluru)

 ((Brijesh.Patel1@thomsonreuters.com; Ph no. +91 9590227221;))

Recent news on Anthem Biosciences

See all news